Abstract Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED). but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised.... https://www.roneverhart.com/Behringer-UL-1000G2-Wireless-In-Ear-Monitoring-System-US-584-to-608-MHz-p31393/